<DOC>
	<DOC>NCT00601562</DOC>
	<brief_summary>The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's RetrovirÂ® 300 mg tablet under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of Zidovudine Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Participation in a clinical trial within 30 days prior to study initiation. Positive blood screen for HIV or Hepatitis B and C. History of allergic or adverse responses to zidovudine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>HIV</keyword>
</DOC>